Every 8-K that Viridian Therapeutics, Inc. (VRDN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VRDN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRDN filings page.
Viridian Therapeutics reported second-quarter 2026 results and significant milestones. Lumvoa (veligrotug-vvze) was approved by the FDA for thyroid eye disease on June 26, 2026, ahead of its target PDUFA date, and was immediately launched in the U.S. Elegrobart remains on track for a planned BLA submission in the first quarter of 2027, while FcRn and TSHR programs are expected to meet 2026 development milestones. The company also completed a May 2026 convertible debt and equity financing with gross proceeds of $394 million.
For the three months ended June 30, 2026, Viridian generated $284 thousand in total revenues and incurred $126,552 thousand of operating expenses, resulting in a net loss of $127,119 thousand, compared with $100,735 thousand a year earlier. Cash, cash equivalents, and marketable securities were $981,530 thousand as of June 30, 2026, supporting total assets of $1,097,233 thousand, liabilities of $435,136 thousand, and stockholders’ equity of $662,097 thousand.
Viridian Therapeutics announced that the FDA has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED) regardless of disease activity or duration. Lumvoa is described as the first TED treatment with labeling that includes data for both active and chronic disease.
The approval is based on the pivotal phase 3 THRIVE (active TED) and THRIVE-2 (chronic TED) trials, which met primary and all secondary endpoints, showing rapid and durable improvements in key signs and symptoms by week 15. Patients received a 12-week course of five intravenous infusions given every three weeks.
Viridian plans to launch Lumvoa immediately and has established the ViridianCares™ support program to help with access, insurance, and financial assistance. The label highlights safety considerations including infusion reactions, hyperglycemia in 12% of patients, potential inflammatory bowel disease exacerbation, and possible severe hearing impairment, as well as common adverse events such as muscle spasms and headache.
Viridian Therapeutics held its 2026 Annual Meeting of Stockholders, where holders of common stock as of the April 7, 2026 record date could vote. As of that date, 103,071,889 shares of common stock were issued and outstanding.
Stockholders elected Class II directors Tomas Kiselak and Jennifer K. Moses to serve until the 2029 annual meeting. Kiselak received 72,363,500 votes for and 14,475,646 withheld, while Moses received 86,378,842 for and 460,304 withheld, with 6,733,104 broker non-votes for each.
Stockholders ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 92,866,008 votes for. They also approved, on an advisory basis, executive compensation and indicated a preference to hold the advisory say-on-pay vote every year, which the board has adopted.
Viridian Therapeutics, Inc. has fully repaid its outstanding term loan, prepaying approximately $55.1 million on May 27, 2026 under its Loan and Security Agreement with Hercules Capital and other lenders. This amount covered all remaining principal, accrued interest, fees, costs and expenses, so all obligations under the agreement were satisfied and discharged.
The Loan Agreement, originally allowing aggregate maximum borrowings of up to $300 million, had funded $50 million to the company. That Term Loan carried a floating interest rate between 8.95% and 9.45% per year and was scheduled to run with interest-only payments into October 2029 or potentially October 2030, with final maturity on October 1, 2030. By paying it off early, Viridian eliminated this high-cost debt and terminated the lending arrangements several years ahead of maturity.
Viridian Therapeutics has signed a Commercial Manufacturing Services Agreement with WuXi Biologics to produce veligrotug drug substance and drug product for commercial use if the therapy is approved. WuXi will act as a non-exclusive supplier, allowing Viridian to use other manufacturers as well.
The deal uses rolling monthly volume forecasts, with a portion becoming a binding purchase commitment, and relies on volume-based pricing. Service fees remain fixed until December 31, 2026, then may be adjusted annually. The agreement runs for an initial five-year term with automatic five-year renewals and includes customary provisions on quality, regulatory compliance, confidentiality, and termination for material breach, insolvency, or certain adverse legal changes.
Viridian Therapeutics completed two major financings, issuing $250,000,000 of 1.75% Convertible Senior Notes due 2032 and closing a public equity offering of 7,352,942 common shares at $17.00 per share.
The notes pay 1.75% interest semiannually and are convertible at an initial rate of 40.5680 shares per $1,000 principal amount, implying a conversion price of about $24.65 per share, with potential increases upon certain “Make-Whole Fundamental Change” events. Net proceeds from the convertible notes were approximately $242.0 million.
The equity offering generated net proceeds of about $117.0 million. Viridian plans to use combined proceeds to repay all outstanding debt under its Hercules Capital loan, fund market expansion studies for its thyroid eye disease franchise, advance earlier-stage R&D, and for working capital and other general corporate purposes.
Viridian Therapeutics reported positive phase 3 REVEAL-2 topline results for elegrobart, a subcutaneous anti‑IGF‑1R antibody in chronic thyroid eye disease (TED). Elegrobart achieved proptosis responder rates of 50% with every‑4‑week dosing and 54% with every‑8‑week dosing at week 24, versus 15% on placebo, with high statistical significance (p < 0.0001).
The Q4W arm also showed a 61% diplopia responder rate at week 24 compared with 38% on placebo (p = 0.0118). Across both dosing regimens, elegrobart was generally well tolerated, with low placebo‑adjusted rates of hearing impairment and 91% of treated patients completing the full course.
Viridian plans a Biologics License Application (BLA) submission for elegrobart in Q1 2027 and highlights that it is the only subcutaneous program with positive phase 3 data in both active and chronic TED. Veligrotug, its intravenous IGF‑1R antibody, has a PDUFA target action date of June 30, 2026, under Priority Review and Breakthrough Therapy Designation, while cash of $762 million as of March 31, 2026 is described as sufficient, together with anticipated milestones and revenues if approvals occur, to fund current plans through profitability.
Viridian Therapeutics reported first quarter 2026 results and key pipeline milestones. The company is preparing for a PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease and has submitted a Marketing Authorization Application in Europe, which was accepted for review.
Subcutaneous elegrobart showed positive topline results in two phase 3 REVEAL trials in active and chronic thyroid eye disease, with a Biologics License Application submission planned in Q1 2027. Viridian ended March 31, 2026 with $762 million in cash, cash equivalents, and short-term investments, generated $141 thousand in total revenues, and recorded a net loss of $104.9 million for the quarter.
Viridian Therapeutics reported positive topline phase 3 data from its REVEAL-1 trial of subcutaneous elegrobart in active thyroid eye disease (TED). The Q4W dosing arm achieved a proptosis responder rate of 54% versus 18% for placebo at week 24, meeting the primary endpoint with high statistical significance. The Q8W arm reached a 63% proptosis responder rate versus 18% placebo, and complete resolution of diplopia occurred in 51% of Q4W patients versus 16% on placebo. Elegrobart was generally well tolerated, with low placebo-adjusted rates of hearing impairment and adverse events consistent with the anti‑IGF‑1R class.
Viridian is also advancing veligrotug for TED, supported by positive phase 3 THRIVE and THRIVE‑2 results, and targets a PDUFA action date of June 30, 2026 for veligrotug and a planned BLA submission for elegrobart in Q1 2027. The company ended Q4 2025 with $875 million in cash and expects cash, potential near-term royalty milestones, and future revenues from veligrotug and elegrobart, if approved, to fund current plans through profitability.
Viridian Therapeutics reported a larger net loss in 2025 while advancing its thyroid eye disease (TED) pipeline toward potential commercialization. For 2025, total revenue was $70.8 million and net loss was $342.6 million, compared with revenue of $0.3 million and net loss of $269.9 million in 2024.
Cash, cash equivalents, and marketable securities were $874.7 million as of December 31, 2025, supporting management’s view that, together with potential milestones and anticipated commercial revenue if veligrotug and elegrobart are approved, current plans can be funded through profitability. Veligrotug’s BLA is under Priority Review with a PDUFA target date of June 30, 2026, and a European MAA was submitted in January 2026. Phase 3 elegrobart REVEAL-1 and REVEAL-2 topline data are expected in Q1 and Q2 2026, and VRDN-008 entered phase 1 with data expected in 2H 2026.
Viridian Therapeutics (VRDN) announced quarterly results by issuing a press release for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 under Item 2.02 of a Form 8-K.
The press release is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act and is not incorporated by reference into other filings. The report was signed by President and Chief Executive Officer Stephen Mahoney.
Viridian Therapeutics (VRDN) announced an underwritten public offering of common stock. The company agreed to sell 11,425,000 shares at $22.00 per share, for aggregate gross proceeds of approximately $251.35 million before underwriting discounts, commissions, and expenses. Underwriters have a 30‑day option to purchase up to an additional 1,713,750 shares on the same terms. The offering was made under an automatically effective shelf registration statement and is expected to close on October 23, 2025.
Viridian states that the net proceeds, together with existing cash and other expected sources— including a $70 million upfront payment receivable from Kissei in the fourth quarter of 2025, the $55 million upfront payment from a purchase and sale agreement with DRI plus $115 million in potential near‑term milestones under that agreement, and $30 million from a term loan facility—should provide sufficient capital to fund currently anticipated operations. The company also references anticipated revenue from veligrotug and VRDN‑003 sales if each is approved on its anticipated timelines.
Viridian Therapeutics (VRDN) announced a preliminary balance of approximately $490.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025. The figure is unaudited and subject to completion of financial closing procedures, and the company’s independent auditor has not performed any review or assurance work on this number. The final amount reported in the upcoming unaudited condensed consolidated balance sheet may differ materially.
Viridian Therapeutics (VRDN) filed an 8-K to disclose a collaboration and license agreement signed 30 Jul 2025 with Japan-based Kissei Pharmaceutical covering two IGF-1R monoclonal antibodies, veligrotug and VRDN-003, for thyroid eye disease and other potential indications in Japan. Kissei receives exclusive Japanese development and commercialization rights and a limited non-exclusive manufacturing right; Viridian retains global rights elsewhere and will supply product.
Financial terms: Kissei will pay $70 million upfront. Viridian is eligible for up to $315 million in development, regulatory and sales milestones. Tiered royalties in the low-20% to mid-30% range on future Japanese sales will follow launch. Kissei funds Japanese clinical, regulatory and commercial activities under joint-steering oversight, reducing Viridian’s cash burden.
Strategic impact: The agreement delivers immediate, non-dilutive capital, extends cash runway and externally validates VRDN-003/veligrotug while preserving all ex-Japan upside. Key execution risks include dependence on Kissei’s development success and Viridian’s ongoing manufacturing obligations.